drugset / Trial / NCT00286429
Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.
Timeline
- Start
- 2006-02
- Primary completion
- 2007-05
- Completion
- 2007-05
Publications
- Results Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009 Dec;11(12):1145-52. doi: 10.1111/j.1463-1326.2009.01124.x. Epub 2009 Sep 16.
- Results Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009 Nov;57(11):2011-9. doi: 10.1111/j.1532-5415.2009.02484.x. Epub 2009 Sep 30.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Alogliptin | Unknown | 25 mg | Oral |
| Comparator | Insulin | Protein / enzyme biologic | — | — |